Skip to main content
Journal ArticleOPEN ACCESS

Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The Paradigm for Monitoring Targeted Cancer Therapy

  • Press R
The Oncologist (2010) 15(7) 744-749
DOI: 10.1634/theoncologist.2010-0055
14Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This article examines the role of real-time quantitative polymerase chain reaction testing of BCR-ABL transcript levels to assess minimal residual disease and outcomes in patients with chronic myeloid leukemia.

Cite

CITATION STYLE

APA

Press, R. D. (2010). Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The Paradigm for Monitoring Targeted Cancer Therapy. The Oncologist, 15(7), 744–749. https://doi.org/10.1634/theoncologist.2010-0055

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free